Get emergency contraception for as low as $0 with insurance →
Get emergency contraception for as low as $0 with insurance →
Semaglutide and tirzepatide are the active ingredients behind several well-known prescription medications.
Semaglutide is sold as Wegovy (FDA-approved for chronic weight management) and Ozempic (approved for type 2 diabetes and commonly prescribed off-label for weight loss).
Tirzepatide is the medication in Zepbound (approved for chronic weight management) and Mounjaro (approved for type 2 diabetes and sometimes used off-label for weight reduction).
These medications are indicated for adults with obesity, or adults who are overweight with weight-related medical conditions such as hypertension, dyslipidemia, prediabetes, or type 2 diabetes.
Semaglutide and tirzepatide appear similar.
Both improve blood sugar regulation.
Both reduce appetite.
Both produce meaningful weight loss.
But they are not interchangeable.
The difference lies in how they communicate with the brain’s appetite centers and metabolic hormones — which changes how hunger, cravings, and calorie intake are experienced.
Many patients describe this as the difference between:
Semaglutide is a GLP-1 receptor agonist.
It mimics the natural hormone GLP-1 released after eating.
GLP-1 signals the body to:
Because GLP-1 receptors exist in the brain’s appetite and reward centers, semaglutide strongly influences eating behavior — not just stomach fullness.
In clinical appetite studies, patients taking semaglutide had:
This is why patients commonly describe a reduction in “food noise” — fewer intrusive food thoughts and less emotional eating.
In the STEP-1 trial, adults with obesity lost an average of 14.9% of body weight at 68 weeks compared to 2.4% with placebo¹.
For many people, semaglutide feels steady and behavior-stabilizing — eating becomes easier to manage rather than forced.
Tirzepatide activates two hormonal pathways instead of one:
This dual incretin signaling produces broader metabolic effects.
Beyond GLP-1 benefits, GIP activity contributes to:
In the SURMOUNT-1 trial, patients lost up to 20.9% of body weight at 72 weeks³.
In the SURPASS-2 head-to-head study, tirzepatide produced greater reductions in both HbA1c and body weight compared with semaglutide 1 mg³⁴.
Clinically, patients often notice:
Rather than quieting thoughts about food, tirzepatide more strongly reduces physical hunger signals
Semaglutide → GLP-1 only
Often especially helpful for reducing cravings and constant thoughts about food.
Tirzepatide → GLP-1 + GIP
Often produces stronger appetite suppression and larger metabolic shifts.
Neither medication is universally “better.”
The best option depends on:
Both medications share similar gastrointestinal side effects:
Symptoms are dose-dependent and most noticeable during dose escalation.
Discontinuation rates in major trials remained under 10%¹³.
Both semaglutide and tirzepatide are powerful metabolic therapies.
Semaglutide often helps patients feel mentally free from cravings and repetitive food thoughts.
Tirzepatide often suppresses hunger more strongly and produces greater average weight reduction.
The most effective medication is not the strongest —
it is the one that matches your physiology and can be used consistently under medical guidance.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
Blundell J, et al. Effects of Once-Weekly Semaglutide 2.4 mg on Appetite, Energy Intake, Control of Eating, and Food Cravings in Adults With Obesity. Diabetes ObesMetab. 2021;23(3):754-762.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216.
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
